Instead of celebrating a landmark HIV prevention drug, aid groups are scrambling to keep those already infected alive after Trump's gutting of the global health infrastructure, @lisamjarvis says (via @opinion) https://t.co/SGDWStQrGQ ...

What what is this latest injectable. Why is it better. It's a milestone moment, Becky, in in the history of HIV.Yes. Tuggo is is potentially the best tool we've had yet and and a number of great tools that could potentially end the epidemic. And the reason why is this is a first of its kind.Um medicine for preventing HIV that's given only twice a year. Uh and in clinical trials, it provided almost 100% protection against HIV, which is really unheard of. So, it's a it's one of the most important scientific b ...

Well, the world has a new wonder drug for preventing HIV AIDS. The FDA approving Gilead's injectable just a few days ago. And joining us right now exclusively to talk about this is Gilead Sciences chairman and CEO Daniel OD.Dan, welcome. Thank you very much for coming here. I I know that this is something you've been working on for a very long time.I think we've been talking about it for over a year at this point, but this is Gilead's focus to try and bring new drugs and hopefully eventually eradicate this ...

Core Insights - Gilead Sciences, Inc. (GILD) received FDA approval for lenacapavir, branded as Yeztugo, a twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg [1][7][10] - Yeztugo is the first and only twice-yearly PrEP option available in the United States, representing a significant advancement in HIV prevention [1][10] - The approval was based on late-stage studies, PURPOSE 1 and PURPOSE 2, which demonstrated that ≥99.9% of participants who received Yeztugo remained HIV-negative [2][8] Company Performance - Year to date, GILD shares have increased by 18.6%, contrasting with a 4% decline in the industry [4] - The approval of Yeztugo enhances Gilead's HIV portfolio, especially as its other prevention drug, Truvada, faces generic competition [12] Competitive Landscape - Yeztugo's long-acting dosing aims to improve PrEP uptake by addressing adherence challenges and stigma associated with daily oral medications [7][10] - Gilead's flagship drug, Biktarvy, holds over 51% of the treatment market share in the United States, indicating strong market positioning [11] - The approval of Yeztugo is expected to catalyze uptake among historically underserved populations, providing a competitive advantage over daily oral pills [11][10] Regulatory and Market Developments - Yeztugo was granted Breakthrough Therapy Designation and has also received validation from the European Medicines Agency for marketing authorization [9] - The approval of long-acting injectable forms of PrEP, such as Yeztugo and ViiV Healthcare's Apretude, indicates a growing trend in HIV prevention strategies [13][14]

Gilead Sciences (GILD) 2025 Conference June 04, 2025 11:05 AM ET Speaker0 Good morning everyone. Welcome to our next panel discussion with Gilead Sciences. We have a couple of important members of the executive team from Gilead here up with us. To my left, Dietmar Berger, who's the new CMO, and I like to say running the hot seat of R and D in front of Wall Street to talk about obviously everything going on in the pipeline. As well as Cindy Paretti. She's Executive Vice President of Kite and runs everything ...